1. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. (1st January 2020) Authors: Duan, Tianjiao; Tradtrantip, Lukmanee; Phuan, Puay-Wah; Bennett, Jeffrey L.; Verkman, Alan S. Journal: Neuropharmacology Issue: Volume 162(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Aquaporin gene therapy for disorders of cholestasis?. Issue 2 (28th May 2016) Authors: Tradtrantip, Lukmanee; Verkman, Alan S. Journal: Hepatology Issue: Volume 64:Issue 2(2016:Aug.) Page Start: 344 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Benzopyrimido‐pyrrolo‐oxazine‐dione CFTR inhibitor (R)‐BPO‐27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. Issue 2 (8th November 2016) Authors: Cil, Onur; Phuan, Puay‐Wah; Gillespie, Anne Marie; Lee, Sujin; Tradtrantip, Lukmanee; Yin, Jianyi; Tse, Ming; Zachos, Nicholas C.; Lin, Ruxian; Donowitz, Mark; Verkman, Alan S. Journal: FASEB journal Issue: Volume 31:Issue 2(2017) Page Start: 751 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Biology of AQP4 and Anti‐AQP4 Antibody: Therapeutic Implications for NMO. (14th October 2013) Authors: Verkman, A. S.; Phuan, Puay‐Wah; Asavapanumas, Nithi; Tradtrantip, Lukmanee Journal: Brain pathology Issue: Volume 23:Number 6(2013:Nov.) Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Emerging therapeutic targets for neuromyelitis optica spectrum disorder. (3rd March 2020) Authors: Tradtrantip, Lukmanee; Asavapanumas, Nithi; Verkman, Alan S. Journal: Expert opinion on therapeutic targets Issue: Volume 24:Number 3(2020:Mar.) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti–aquaporin‐4 immunoglobulin G into therapeutic antibody. Issue 1 (10th October 2012) Authors: Tradtrantip, Lukmanee; Ratelade, Julien; Zhang, Hua; Verkman, A. S. Journal: Annals of neurology Issue: Volume 73:Issue 1(2013:Jan.) Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. (1st May 2018) Authors: Tradtrantip, Lukmanee; Felix, Christian M.; Spirig, Rolf; Morelli, Adriana Baz; Verkman, A.S. Journal: Neuropharmacology Issue: Volume 133(2018) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Targeting the complement system in neuromyelitis optica spectrum disorder. (3rd August 2021) Authors: Asavapanumas, Nithi; Tradtrantip, Lukmanee; Verkman, Alan S. Journal: Expert opinion on biological therapy Issue: Volume 21:Number 8(2021) Page Start: 1073 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The aquaporin-4 water channel as a potential drug target in neurological disorders. (2nd December 2017) Authors: Verkman, Alan S.; Smith, Alex J.; Phuan, Puay-wah; Tradtrantip, Lukmanee; Anderson, Marc O. Journal: Expert opinion on therapeutic targets Issue: Volume 21:Number 12(2017:Dec.) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗